Evidence map›Paper›PMID 41107511›Full record

ArticleArchives of gynecology and obstetrics2025

Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis.

Dominik Dannehl, Tjeerd Maarten Hein Dijkstra, Alexandra von Au, Anna Sophie Scholz, Léa Louise Volmer, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Florin-Andrei Taran, Markus Wallwiener and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dominik DannehlDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany. Dominik.Dannehl@med.uni-tuebingen.de.
Tjeerd Maarten Hein DijkstraDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Alexandra von AuDepartment of Gynecology and Obstetrics, Heidelberg University, Heidelberg, Germany.
Anna Sophie ScholzDepartment of Gynecology and Obstetrics, Heidelberg University, Heidelberg, Germany.
Léa Louise VolmerDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Markus HahnDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Sabine Hawighorst-KnapsteinAOK Baden-Wuerttemberg, Stuttgart, Germany.
Ariane ChaudhuriAOK Baden-Wuerttemberg, Stuttgart, Germany.
Florin-Andrei TaranDepartment of Gynecology and Gynecologic Oncology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Markus WallwienerUniversity Hospital for Gynecology, Halle University, Halle, Germany.
Armin BauerDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Diethelm WallwienerDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Sara Yvonne BruckerDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Stephanie WallwienerUniversity Hospital for Prenatal Medicine and Obstetrics, Halle, Germany.
Andreas HartkopfDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.
Tobias EnglerDepartment of Women's Health, Tuebingen University, Calwerstraße 7, 72076, Tuebingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMale breast cancer (BC) is a rare entity and represents a significant clinical challenge due to its late diagnosis and resulting poorer prognosis compared to female BC. As shown by prior studies, approximately 99% of male BC patients are hormone receptor-positive (HR +). This study aimed to evaluate the utilization and impact of adjuvant endocrine therapy (ET) in male early BC patients using a large German real-world claims dataset. PATIENTS AND

methodsData were collected from a major German statutory health insurance provider (AOK Baden-Wuerttemberg) covering the period between January 1, 2010, and December 31, 2020. Male patients diagnosed with early BC who underwent breast surgery were included. ET use was determined by prescription records. The impact of ET on overall survival (OS) was assessed using univariable (log-rank) and multivariable (cox regression) analysis.

resultsAmong 128 male early BC patients, 16% (n = 21) did not utilize adjuvant ET. On univariable analysis, ET was significantly associated with 5-year OS (74% with ET vs. 37% without ET; p < 0.0001). Multivariable analysis revealed ET use (Hazard Ratio [HR]: 0.31, 95% CI 0.14-0.69, p = 0.004) having a positive effect on OS, whereas age (HR: 1.04, 95% CI 1.00-1.09) and comorbidities (HR: 1.18, 95% CI 1.05-1.34, p = 0.007) were identified as negative predictive factors for OS.

conclusionA significant proportion of male patients with early BC does not use ET. However, the use of ET plays a key role in improving survival outcomes for male patients with early BC. Efforts to improve the use of ET, including patient education and management of side effects, are essential to optimize treatment outcomes.

Indexed as

Antineoplastic Agents, HormonalBreast Neoplasms, MaleAdultAgedChemotherapy, AdjuvantGermanyHumansMaleMiddle AgedRetrospective StudiesAntineoplastic Agents, HormonalAdherenceEndocrine therapyMale breast cancerOutcome

Identifiers

PMID41107511
PMCPMC12705814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.